Infectious Disease and Glycoscience Lab
Research Field
I received my Ph.D. from the Taiwan International Graduate Program, Academia Sinica, in collaboration with National Yang Ming Chiao Tung University, where my research focused on epigenetic regulation of immunosuppressive Siglec ligand glycans in early-stage colon cancer. During my postdoctoral training at Academia Sinica and the University of Gothenburg, I further expanded my expertise in viral immunology and host-directed antiviral strategies. Through interdisciplinary and international collaborations, I am committed to advancing our understanding of infectious diseases and translating these insights into innovative therapeutic interventions.
Translationally, our lab is dedicated to developing innovative therapeutic strategies. These include targeting aberrant host glycosylation pathways, as well as engineering exosome-based platforms for antiviral delivery and immune modulation. Through these efforts, we aim to identify novel therapeutic targets and intervention strategies to combat emerging viral threats and their long-term pathological consequences.
III. RNA Biology and Antiviral Defense Mechanisms
- Examining the role of nuclear RNA interference (RNAi) in regulating innate immune responses against viral infections.
- Developing RNA-based therapeutic approaches to modulate host immune responses and inhibit viral replication.
IV. Multi-Omics and AI-Driven Modeling of Virus-Host Interactions
- Applying AI-driven modeling to predict receptor-virus interactions and identify potential antiviral drug targets.
- Integrating machine learning algorithms with multi-omics data to uncover novel therapeutic strategies against viral infections and co-infections.
2012 – 2015 Studying Abroad Scholarship, TIGP, Taiwan
Dissertation Topic: Epigenetic silencing of the synthesis of immunosuppressive Siglec ligand glycans by NF-kB/EZH2/YY1 axis in early-stage colon cancers.
Supervisor: Reiji Kannagi, M.D., Ph.D.